GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » Debt-to-EBITDA

RDNT (RadNet) Debt-to-EBITDA : 6.12 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is RadNet Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RadNet's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $82 Mil. RadNet's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,655 Mil. RadNet's annualized EBITDA for the quarter that ended in Sep. 2024 was $284 Mil. RadNet's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 6.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RadNet's Debt-to-EBITDA or its related term are showing as below:

RDNT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.34   Med: 5.23   Max: 5.93
Current: 5.35

During the past 13 years, the highest Debt-to-EBITDA Ratio of RadNet was 5.93. The lowest was 4.34. And the median was 5.23.

RDNT's Debt-to-EBITDA is ranked worse than
84.26% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.805 vs RDNT: 5.35

RadNet Debt-to-EBITDA Historical Data

The historical data trend for RadNet's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RadNet Debt-to-EBITDA Chart

RadNet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.25 5.93 5.02 5.43 5.09

RadNet Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 3.18 5.72 6.14 6.12

Competitive Comparison of RadNet's Debt-to-EBITDA

For the Diagnostics & Research subindustry, RadNet's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RadNet's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RadNet's Debt-to-EBITDA falls into.



RadNet Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RadNet's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(73.955 + 1417.165) / 292.786
=5.09

RadNet's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(82.129 + 1654.706) / 283.988
=6.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


RadNet  (NAS:RDNT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


RadNet Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RadNet's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RadNet Business Description

Traded in Other Exchanges
Address
1510 Cotner Avenue, Los Angeles, CA, USA, 90025
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
Executives
David Jeffrey Katz officer: EVP and General Counsel 1510 COTNER AVE, LOS ANGELES CA 90025
Ranjan Jayanathan officer: Chief Information Officer 13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Michael N Murdock officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Gregory E. Spurlock director 4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
Mital Patel officer: Executive Vice President 1510 COTNER AVENUE, LOS ANGELES CA 90025
Lawrence L Levitt director 2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Gregory Sorensen director, officer: EVP Chief Science Officer C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Stephen M Forthuber officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
David L Swartz director 1510 COTNER AVENUE, LOS ANGELES CA 90025
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Christine Nayoma Gordon director 3081 PANAMA AVE., CARMICHAEL CA 95608
Norman R Hames director, officer: Vice President
Ruth Louisa Villigerwilson director, officer: Senior Vice President 3700 WALNUT AVENUE, LONG BEACH CA 90801
John V Crues director 1510 COTNER AVE, LOS ANGELES CA 90025
Laura Pastre Jacobs director 10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064